Related Experiment Video
Updated: Apr 16, 2026

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
Published on: April 16, 2019
T1 glottic carcinoma: do comorbidities, facility characteristics, and sociodemographics explain survival differences
Stephanie Misono1, Schelomo Marmor2, Bevan Yueh3
1Department of Otolaryngology/Head and Neck Surgery, University of Minnesota, Minneapolis, Minnesota, USA smisono@umn.edu.
Objective:
Recent large-scale studies have observed differences in survival following treatment for early laryngeal carcinoma depending on treatment type but were not able to take sociodemographic, comorbidity, and facility data into account. The objective of this study was to determine whether survival differences across treatment types persist when these factors are included in the analysis.
Study Design:
Retrospective cohort analysis.
Setting:
Linked Surveillance, Epidemiology, and End Results (SEER)-Medicare data files.
Subjects And Methods:
Medicare beneficiaries who were identified through the SEER registries (1991-2009) as having T1 glottic squamous cell carcinoma (scca) and a known treatment type were included.
Results:
A total of 2338 patients with incident T1 glottic scca were identified. Most were white and male. Treatment type was radiation only in 47%, local surgery and radiation in 39%, and local surgery only in 14%. Black race and increased comorbidities were associated with worse survival. When sociodemographics, comorbidities, and facility characteristics were taken into account, survival differences were observed across treatment types, with those receiving local surgery demonstrating better overall and cancer-specific survival.
Conclusion:
These results suggest that following treatment of T1 glottic scca, there may be survival differences across treatment types beyond those explained by sociodemographic, comorbidity, and facility characteristics.
Related Concept Videos
Cancer Survival Analysis
Treatment Resistant Cancers
Treatment Resistent Cancers
Comparing the Survival Analysis of Two or More Groups
Tumor Immunotherapy
